AQP4 and Alzheimer disease: Notably, proteomic data from post-mortem brains of more than 500 individuals from Agora, a platform initially developed by the NIA-funded AMP-AD consortium that shares evidence in support of AD target discovery, has revealed that AD brains (dorsolateral prefrontal cortex) display significantly higher levels of AQP4 compared to controls (https://agora.adknowledgeportal.org/, accessed date on 13 September 2022).